Asciminib Hydrochloride is a selective tyrosine kinase inhibitor and STAMP (Specifically Targeting the ABL Myristoyl Pocket) agent indicated for the treatment of Philadelphia chromosome-positive chronic… Read more
Asciminib Hydrochloride is a selective tyrosine kinase inhibitor and STAMP (Specifically Targeting the ABL Myristoyl Pocket) agent indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. This category contains high-quality reference standards essential for pharmaceutical laboratories engaged in rigorous quality control, regulatory assessment, and impurity profiling. By specifically inhibiting the BCR-ABL1 fusion protein, the parent drug requires precise analytical testing to ensure product consistency. Laboratories utilize these compounds, including both pharmacopeial and non-pharmacopeial impurities, to support method validation and facilitate accurate detection during drug synthesis and degradation studies. Furthermore, stable isotope-labelled compounds are included to serve as internal standards for the quantification of the drug and its metabolites within complex bioanalytical workflows, ensuring reliable results in stability testing and compliance with industry standards.